A synbiotic anti-inflammatory dietary supplement (SADS) containing Lactobacillus rhamnosus GG, Hericium erinaceus, berberine, quercetin, palmitoylethanolamide, and Undaria administered daily for one month significantly reduced bowel movement frequency, abdominal pain, and fecal calprotectin levels in SUDD patients with persistent diarrheal symptoms following rifaximin therapy.
Daily bowel movement frequency significantly decreased after one month of SADS treatment compared to baseline.
Abdominal Pain Score improved significantly following one month of SADS treatment.
Fecal calprotectin levels decreased significantly following SADS treatment.
Treatment satisfaction was significantly negatively correlated with both abdominal pain scores and daily bowel movement frequency.
The SADS supplement contained multiple bioactive components targeting inflammation and gut microbiota.
Current treatment strategies for symptomatic uncomplicated diverticular disease remain controversial, and nutraceuticals are proposed as potential adjuvant treatments.
This research suggests that a multi-ingredient dietary supplement combining a probiotic (Lactobacillus rhamnosus GG), a medicinal mushroom (Hericium erinaceus), and several anti-inflammatory compounds (berberine, quercetin, palmitoylethanolamide, and Undaria seaweed) may help relieve symptoms in people with symptomatic uncomplicated diverticular disease (SUDD) — a condition where small pouches in the colon cause ongoing abdominal pain and bowel problems. The 54 patients studied had already received antibiotic treatment with rifaximin but still had persistent diarrhea. After one month of taking this supplement daily, they experienced significantly fewer daily bowel movements, less abdominal pain, and lower levels of a stool marker (calprotectin) that indicates intestinal inflammation. Nearly 9 out of 10 patients reported moderate-to-high satisfaction with the treatment. This research suggests that this type of combination supplement could be a useful add-on treatment for people with SUDD whose symptoms persist after standard antibiotic therapy. The reduction in fecal calprotectin — from abnormal levels in 100% of patients before treatment to abnormal levels in only 65% after treatment — indicates the supplement may also reduce gut inflammation, not just symptom perception. However, because this was a retrospective, real-world study without a control group, it is not possible to rule out other explanations for the improvements, such as natural symptom fluctuation over time. The authors themselves call for prospective clinical trials with control groups to confirm whether this supplement is truly effective.
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Upload Your LabsBertani L, Chico L, Balestrini L, Della Scala G, Satriano A, Manta R. (2026). A multi-compound dietary supplement to improve the well-being of symptomatic uncomplicated diverticular disease.. Minerva gastroenterology. https://doi.org/10.23736/S2724-5985.26.04100-8